Supplementary Table S2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses

Supplementary Table S2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses

<p>Supplemental Table S2 - Differential expression analysis of genes in leukemic or immune cells treated with sEV</p>

Saved in:

書目詳細資料
主要作者:	Ernesto Gargiulo (15134961) (author)
其他作者:	Elodie Viry (15134964) (author), Pablo Elías Morande (15134967) (author), Anne Largeot (15134970) (author), Susanne Gonder (15134973) (author), Feng Xian (15134976) (author), Nikolaos Ioannou (15134979) (author), Mohaned Benzarti (15134982) (author), Felix Bruno Kleine Borgmann (15134985) (author), Michel Mittelbronn (15134988) (author), Gunnar Dittmar (15134991) (author), Petr V. Nazarov (15134994) (author), Johannes Meiser (15134997) (author), Basile Stamatopoulos (15135000) (author), Alan G. Ramsay (15021857) (author), Etienne Moussay (15135003) (author), Jérôme Paggetti (15135006) (author)
出版:	2025
主題:	Cancer Tumor Biology Immuno-oncology Methods and Technology Hematological Cancers Leukemias Lymphomas Immunology T cell exhaustion Tumor resistance to immune response Preclinical Models Animal models of cancer Tumor Microenvironment Immune cells and the microenvironment
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Figure 1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
由: Ernesto Gargiulo (15134961)
出版: (2025)

Figure 2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
由: Ernesto Gargiulo (15134961)
出版: (2025)

Figure 3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
由: Ernesto Gargiulo (15134961)
出版: (2025)

Figure 4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
由: Ernesto Gargiulo (15134961)
出版: (2025)

Figure 5 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
由: Ernesto Gargiulo (15134961)
出版: (2025)

Figure 6 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
由: Ernesto Gargiulo (15134961)
出版: (2025)

Figure 7 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
由: Ernesto Gargiulo (15134961)
出版: (2025)

Supplementary Table S1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
由: Ernesto Gargiulo (15134961)
出版: (2025)

Supplementary Table S3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
由: Ernesto Gargiulo (15134961)
出版: (2025)

Supplementary Table S4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
由: Ernesto Gargiulo (15134961)
出版: (2025)

Table S1 from HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion
由: Andrew Nguyen (17142197)
出版: (2025)

Supplementary Figure S1 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
由: Shih-Shih Chen (15314296)
出版: (2025)

Supplementary Figure S2 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
由: Shih-Shih Chen (15314296)
出版: (2025)

Supplementary Figure S3 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
由: Shih-Shih Chen (15314296)
出版: (2025)

Supplementary Figure S4 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
由: Shih-Shih Chen (15314296)
出版: (2025)

Supplementary Figure S5 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
由: Shih-Shih Chen (15314296)
出版: (2025)

Supplementary Figure S6 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
由: Shih-Shih Chen (15314296)
出版: (2025)

Supplementary Table S1 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
由: Shih-Shih Chen (15314296)
出版: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
由: Yu Chen (1234761)
出版: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
由: Yu Chen (1234761)
出版: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
由: Yu Chen (1234761)
出版: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
由: Yu Chen (1234761)
出版: (2025)

Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
由: Andrew O. Yam (15293045)
出版: (2025)

Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
由: Andrew O. Yam (15293045)
出版: (2025)

Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
由: Andrew O. Yam (15293045)
出版: (2025)

Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
由: Andrew O. Yam (15293045)
出版: (2025)

Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
由: Andrew O. Yam (15293045)
出版: (2025)

Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
由: Erika Y. Faraoni (14844897)
出版: (2025)

Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
由: Erika Y. Faraoni (14844897)
出版: (2025)

Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
由: Erika Y. Faraoni (14844897)
出版: (2025)

Table S1 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
由: Fanfan Fan (16799646)
出版: (2025)

Table S2 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
由: Fanfan Fan (16799646)
出版: (2025)

Table S3 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
由: Fanfan Fan (16799646)
出版: (2025)

Table S4 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
由: Fanfan Fan (16799646)
出版: (2025)

Table S5 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
由: Fanfan Fan (16799646)
出版: (2025)

Table S6 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
由: Fanfan Fan (16799646)
出版: (2025)

Table S7 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
由: Fanfan Fan (16799646)
出版: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
由: Isha Mondal (16721699)
出版: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
由: Dahihm Kim (16546203)
出版: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
由: Dahihm Kim (16546203)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_m6sna8h1skd1kbpd68uj1b6ooe